Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof
Methods and compositions for the diagnosis of cancer susceptibilities, defective DNA repair mechanisms and treatments thereof are provided. Among sequences provided here, the FANCD2 gene has been identified, and probes and primers are provided for screening patients in genetic-based tests and for diagnosing Fanconi Anemia and cancer. The FANCD2 gene can be targeted in vivo for preparing experimental mouse models for use in screening new therapeutic agents for treating conditions involving defective DNA repair. The FANCD2 polypeptide has been sequenced and has been shown to exist in two isoforms identified as FANCD2-S and the monoubiquinated FANCD-L form. Antibodies including polyclonal and monoclonal antibodies have been prepared that distinguish the two isoforms and have been used in diagnostic tests to determine whether a subject has an intact Fanconi Anemia/BRCA pathway.
1. An in vitro method of predicting the efficacy of a therapeutic agent in a cancer patient, comprising the steps of:
a) taking a tissue sample from said cancer patient who is being treated with said therapeutic agent;
b) inducing DNA damage in the cells of said tissue sample; and
c) detecting the presence of FANCD2-L protein in said cells,
wherein the presence of FANCD2-L protein is indicative of a reduced efficacy of said therapeutic agent in said cancer patient, and wherein said therapeutic agent is cisplatin.
2. The method of claim 1 , wherein said cancer is breast cancer, ovarian cancer, or prostate cancer.